The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of the mind-wasting disease. (Reporting by Baranjot Kaur in Bengaluru; Editing by Stephen Coates)